Alfred Scheidegger, the Founder and Managing Partner of Nextech Invest. See contact routes.
Alfred Scheidegger, the Founder and Managing Partner of Nextech Invest, exclusively invests in oncology therapeutics and precision medicine, targeting promising drug discovery companies from inception through crossover rounds in the US and Europe. His distinctive thesis centers on bridging scientific innovation with effective cancer treatments by providing rigorous scientific validation and long-term capital to build resilient biotech firms. Notable portfolio companies include Blueprint Medicines, MacroGenics, Kura Oncology, and TetraLogic Pharmaceuticals, many of which achieved successful IPOs or corporate acquisitions under his strategic direction. While specific check sizes are not publicly disclosed, the firm has raised over $1 billion in total capital commitments, including a $530 million fund in 2021 and a $412 million fund in 2023.
Every field above is read from the StartupFundraising investor directory — disclosed location, recorded investments and stated focus — and re-checked as filings arrive. Founders pair it with investors in Zürich when building a target list.
Investors like Alfred Scheidegger · Full investor directory · Investor access · Company funding database